High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Abstract Text:

Rui Henrique,Franclim R Ribeiro,Daniel Fonseca,Mohammad O Hoque, Carvalho,Vera L Costa,Mafalda Pinto,Jorge Oliveira,Manuel R Teixeira,David Sidransky,Carmen ,Rui Henrique,Franclim R Ribeiro,Daniel Fonseca,Mohammad O Hoque, Carvalho,Vera L Costa,Mafalda Pinto,Jorge Oliveira,Manuel R Teixeira,David Sidransky,Carmen ,

PURPOSE: Prostate cancer is a highly prevalent malignancy and constitutes a major cause of cancer-related morbidity and mortality. Owing to the limitations of current clinical, serologic, and pathologic parameters in predicting disease progression, we sought to investigate the prognostic value of promoter methylation of a small panel of genes by quantitative methylation-specific PCR (QMSP) in prostate biopsies. EXPERIMENTAL DESIGN: Promoter methylation levels of APC, CCND2, GSTP1, RARB2, and RASSF1A were determined by QMSP in a prospective series of 83 prostate cancer patients submitted to sextant biopsy. Clinicopathologic data [age, serum prostate-specific antigen (PSA), stage, and Gleason score] and time to progression and/or death from prostate cancer were correlated with methylation findings. Log-rank test and Cox regression model were used to identify which epigenetic markers were independent predictors of prognosis. RESULTS: At a median follow-up time of 45 months, 15 (18%) patients died from prostate cancer, and 37 (45%) patients had recurrent disease. In univariate analysis, stage and hypermethylation of APC were significantly associated with worse disease-specific survival, whereas stage, Gleason score, high diagnostic serum PSA levels, and hypermethylation of APC, GSTP1, and RASSF1A were significantly associated with poor disease-free survival. However, in the final multivariate analysis, only clinical stage and high methylation of APC were significantly and independently associated with unfavorable prognosis, i.e., decreased disease-free and disease-specific survival. CONCLUSIONS: High-level APC promoter methylation is an independent predictor of poor prognosis in prostate biopsy samples and might provide relevant prognostic information for patient management.

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Publishing Authors By Initials

R Henrique,FR Ribeiro,D Fonseca,MO Hoque,AL Carvalho,VL Costa,M Pinto,J Oliveira,MR Teixeira,D Sidransky,C ,R Henrique,FR Ribeiro,D Fonseca,MO Hoque,AL Carvalho,VL Costa,M Pinto,J Oliveira,MR Teixeira,D Sidransky,C ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 6122-9

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 15

MONTH: Oct

YEAR: 2007

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.

AFFILIATION: Department of Pathology, Portuguese Oncology Institute--Porto, Portugal.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients Related Publications

• Association of nutritional status with the response to infection with Leishmania chagasi.
• Effect of abiotic factors on seasonal population dynamics of Lutzomyia longipalpis (Diptera: Psychodidae) in northeastern Brazil.
• High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
• Steps towards a repertoire of comprehensive maps of human protein interaction networks: the Human Proteotheque Initiative (HuPI).